NKTR News and Press, Nektar Therapeutics From 05/24/23

2023-05-24 13:57:04 ET The Russell 3000 index will have a new look on June 26, after the market opens, when 286 securities will be added and 179 securities will be deleted as part of the annual reconstitution. Following are some notable healthcare companies which will be added an...

2023-05-09 22:14:06 ET Nektar Therapeutics (NKTR) Q1 2023 Earnings Conference Call May 9, 2023 17:00 ET Company Participants Vivian Wu - Investor Relations Howard Robin - President and Chief Executive Officer Jonathan Zalevsky - Chief, Research and Development ...

2023-05-09 16:18:14 ET Nektar Therapeutics press release ( NKTR ): Q1 GAAP EPS of -$0.73 misses by $0.47 . Revenue of $21.6M (-12.9% Y/Y) beats by $2.17M . Shares -1.9% . Cash and investments in marketable securities at March 31, 2023, were $456.8 milli...

Nektar Therapeutics Reports First Quarter 2023 Financial Results PR Newswire SAN FRANCISCO , May 9, 2023 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the first quarter ended March 31, 2023 . Cash and ...

2023-05-08 17:35:57 ET Nektar Therapeutics ( NASDAQ: NKTR ) is scheduled to announce Q1 earnings results on Tuesday, May 9th, after market close. The consensus EPS Estimate is -$0.24 and the consensus Revenue Estimate is $19.43M (-21.7% Y/Y). Over the last 3 months, EP...

2023-05-08 17:35:56 ET Major earnings expected after the bell on Tuesday include: Airbnb ( ABNB ) Occidental Petroleum Corporation ( OXY ) Twilio ( TWLO ) Virgin Galactic Holdings ( SPCE ) Upstart Holdings ( UPST ) For further details see: ...

2023-04-27 10:14:00 ET Eli Lilly ( LLY ) is returning the rights to atopic dermatitis candidate rezpegaldesleukin (REZPEG) back to Nektar Therapeutics ( NASDAQ: NKTR ). Earlier in April, Nektar ( NKTR ) said it would move REZPEG forward this year in a phase 2 t...

Nektar Therapeutics Announces It Will Regain Full Rights to Rezpegaldesleukin (REZPEG, NKTR-358), a Novel, First-in-Class Selective Regulatory T-cell (Treg) Therapy in Clinical Development PR Newswire Company plans to move REZPEG forward into Phase 2 clinical study in atopic d...

2023-04-18 03:12:29 ET As part of the reorganization initiative , Nektar ( NASDAQ: NKTR ) also announced several changes to its executive team: Dr. Brian Kotzin, Nektar's Chief Medical Officer, will be stepping down from his full-time role but will continue to serve in an...

2023-04-17 17:46:12 ET Nektar Therapeutics ( NASDAQ: NKTR ) will implement a reprioritization and cost restructuring plan that also involves a new pipeline focus on immunology. The biotech will also cut its San Francisco-based workforce by 60%, leaving it with ~55 emp...